ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Moxifloxacin

Also written as “Avelox (Moxifloxacin, BAY12-8039)”, “Moxifloxacin (Avelox, BAY12-8039)” and “moxifloxacin”.

Its studies are mostly in Cataract · Conjunctivitis, Bacterial · Otitis Media · Sinusitis · Community-Acquired Pneumonia, led by 14 companies.

Drug pageMoxifloxacin: every studyMany companies study it; this page follows only the 55 they lead. All 201 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 26, 200755 company-led studies, 2 open or runningNext primary completion: Oct 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayerits history only200 open or runningphase 4since Jun 26, 2007Nov 21, 2006none ahead
Alconits history only140 open or runningphase 4since Apr 4, 2006Apr 4, 2006none ahead
Pfizerits history only40 open or runningphase 1since Jul 10, 2007Jul 10, 2007none ahead
GlaxoSmithKlineits history only30 open or runningphase 1since Oct 8, 2009Oct 8, 2009none ahead
Da Volterraits history only20 open or runningphase 1since Jun 25, 2014Jun 25, 2014none ahead
Laboratorios Sophia S.A de C.V.its history only21 open or runningphase 3since Jul 30, 2025Apr 9, 2024none ahead
Richmond Pharmacologyits history only20 open or runningphase 1since Jun 19, 2012Jun 19, 2012none ahead
Viatrisits history only20 open or runningphase 1since Sep 7, 2005Sep 7, 2005none ahead
Adapt Produtos Oftalmológicos Ltda.its history only10 open or runningphase 3since Mar 22, 2011Mar 22, 2011none ahead
Dr. Reddy's Laboratoriesits history only10 open or runningphase 1since Dec 18, 2014Dec 18, 2014none ahead
Jason Ahee, M.D.11 open or runningphase 3since Aug 4, 2017Aug 4, 2017Oct 2030phase 3 · NCT03244072

Also a collaborator on its studies: AbbVie, Parexel, Bristol-Myers Squibb, Topical Solutions and Shionogi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Jason Ahee, M.D. only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 4, 2017First study: phase 3 study in EndophthalmitisFirst studyNCT03244072 · 60,000 planned · United States

Ahead

  1. Oct 2030Primary completion: phase 3 study in EndophthalmitisNCT03244072

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor”ChEMBL 37, by rule

Studies

The one study Jason Ahee, M.D. leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03244072Endophthalmitis · United States3Not yet recruitingOct 203060,000

How it is read

Names in the registry

  • “Moxifloxacin”, 32 entries
  • “Avelox (Moxifloxacin, BAY12-8039)”, 11 entries
  • “Moxifloxacin (Avelox, BAY12-8039)”, 9 entries
  • “moxifloxacin”, 6 entries
  • “Moxidex otic solution”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.